7Baggers

Soleno Therapeutics, Inc
(NASDAQ:SLNO) 

SLNO stock logo

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Wi...

Founded: 1999
Full Time Employees: 13
Sector: Healthcare
Industry: Diagnostics & Research
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 
                                                   
      product revenue
    		94,603,000 91,730,000 66,018,000 32,657,000                                1,000 265,000 283,788 329,000 391,000 447,000 241,555 92,000 32,000    
      operating expenses
    		                                               
      cost of goods sold
    		1,198,000 863,000 1,141,000 696,000                                            
      research and development
    		11,274,000 9,558,000 8,405,000 9,147,000 13,517,000 21,486,000 30,138,000 12,342,000 14,602,000 8,689,000 6,043,000 5,141,000 5,316,000 3,810,000 3,771,000 3,696,000 3,988,000 3,734,000 4,968,000 5,587,000 7,164,000 5,566,000 4,827,000 6,103,000 6,695,000 5,272,000 4,490,000 3,745,000 2,760,000 2,192,000 2,092,000 1,714,000 1,180,000 1,022,742 982,000 974,000 994,000 953,803 1,131,000 1,327,000 1,772,000 1,284,244 1,193,000 1,181,000 878,000 609,216 717,000 
      selling, general and administrative
    		50,369,000 40,878,000 33,753,000 28,238,000 29,259,000                                           
      change in fair value of contingent consideration
    		484,000 854,000 614,000 1,101,000 2,967,000 327,000 877,000 1,637,000 401,000 1,081,000 1,021,000 313,000 299,000 -602,000 132,000 616,000 -858,000 -3,329,000 551,000 3,034,000 -987,000 140,000 774,000 2,842,000 584,000 -128,000 28,000 183,000 206,000 -22,000 228,000 -67,000 428,000               
      total operating expenses
    		63,325,000 52,153,000 43,913,000 39,182,000 45,743,000 59,116,000 80,212,000 24,868,000 23,475,000 13,910,000 10,382,000 8,623,000 8,469,000 5,610,000 6,235,000 6,779,000 5,773,000 3,001,000 8,286,000 11,085,000 9,156,000 7,957,000 7,857,000 11,193,000 9,282,000 6,752,000 6,133,000 5,623,000 4,978,000 3,535,000 3,878,000 3,413,000 3,475,000               
      operating income
    		31,278,000 39,577,000 22,105,000 -6,525,000 -45,743,000 -59,116,000 -80,212,000 -24,868,000 -23,475,000 -13,910,000 -10,382,000 -8,623,000 -8,469,000 -5,610,000 -6,235,000 -6,779,000 -5,773,000 -3,001,000 -8,286,000 -11,085,000 -9,156,000 -7,957,000 -7,857,000 -11,193,000 -9,282,000 -6,752,000 -6,133,000 -5,623,000 -4,978,000 -3,535,000 -3,878,000 -3,413,000 -3,475,000 -5,199,315 -2,689,000 -3,210,000 -2,210,000 -2,956,115 -2,941,000 -3,450,000 -4,263,000 -3,506,746 -3,183,000 -3,044,000 -2,426,000 -1,845,729 -1,323,000 
      yoy
    		-168.38% -166.95% -127.56% -73.76% 94.86% 324.99% 672.61% 188.39% 177.19% 147.95% 66.51% 27.20% 46.70% 86.94% -24.75% -38.85% -36.95% -62.28% 5.46% -0.96% -1.36% 17.85% 28.11% 99.06% 86.46% 91.00% 58.15% 64.75% 43.25% -32.01% 44.22% 6.32% 57.24% 75.88% -8.57% -6.96% -48.16% -15.70% -7.60% 13.34% 75.72% 89.99% 140.59%     
      qoq
    		-20.97% 79.04% -438.77% -85.74% -22.62% -26.30% 222.55% 5.93% 68.76% 33.98% 20.40% 1.82% 50.96% -10.02% -8.02% 17.43% 92.37% -63.78% -25.25% 21.07% 15.07% 1.27% -29.80% 20.59% 37.47% 10.09% 9.07% 12.96% 40.82% -8.84% 13.62% -1.78% -33.16% 93.35% -16.23% 45.25% -25.24% 0.51% -14.75% -19.07% 21.57% 10.17% 4.57% 25.47% 31.44% 39.51%  
      operating margin %
    		Infinity% Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -11027.27% -Infinity% NaN% 
      other income
    		                                         -1,102,750 -110,000 4,925,000  -3,690,475 -318,000 
      interest income
    		4,927,000 5,130,000 5,298,000 3,193,000 3,331,000 3,365,000 3,596,000 3,014,000 2,077,000 2,144,000 174,000 147,000 113,000 125,000 101,000 52,000 22,000 34,000 34,000 41,000 1,000 3,250 1,000 1,000 11,000 33,250 29,000 47,000 57,000     1,750 4,000 3,000 1,000         85  
      interest expense
    		-1,292,000 -1,349,000 -1,390,000 -1,376,000 -1,361,000                                     -250      
      total other income
    		3,635,000 3,781,000 3,908,000 1,817,000 1,970,000 3,134,000 3,596,000 3,014,000 2,077,000 2,614,000 -479,000 148,000 113,000 124,000 103,000 54,000 49,000 173,000 146,000 97,000 202,000 5,105,000 -688,000 3,809,000 3,424,000 -7,873,000 7,022,000 -4,385,000 -2,052,000 3,928,000 1,569,000 -3,801,000 234,000               
      income before provision for income taxes
    		34,913,000                                               
      provision for income taxes
    		3,535,000                                               
      net income
    		31,378,000 43,358,000 26,013,000 -4,708,000 -43,773,000 -55,982,000 -76,616,000 -21,854,000 -21,398,000 -11,296,000 -10,861,000 -8,475,000 -8,356,000 -5,486,000 -6,132,000 -6,725,000 -5,724,000 -2,828,000 -8,140,000 -10,988,000 -8,954,000 -2,852,000 -8,545,000 -7,384,000 -5,858,000 -14,625,000 889,000 -10,008,000 -7,030,000 263,000 -2,736,000 -7,637,000 -3,755,000 -5,025,425 -3,786,000 -3,966,000 -2,887,000 -2,613,214 -2,750,000 -3,513,000 -3,189,000 -2,844,546 -3,293,000 1,881,000 -11,651,000   
      yoy
    		-171.68% -177.45% -133.95% -78.46% 104.57% 395.59% 605.42% 157.86% 156.08% 105.91% 77.12% 26.02% 45.98% 93.99% -24.67% -38.80% -36.07% -0.84% -4.74% 48.81% 52.85% -80.50% -1061.19% -26.22% -16.67% -5660.84% -132.49% 31.05% 87.22% -105.23% -27.73% 92.56% 30.07% 92.31% 37.67% 12.89% -9.47% -8.13% -16.49% -286.76% -72.63%       
      qoq
    		-27.63% 66.68% -652.53% -89.24% -21.81% -26.93% 250.58% 2.13% 89.43% 4.01% 28.15% 1.42% 52.31% -10.53% -8.82% 17.49% 102.40% -65.26% -25.92% 22.72% 213.96% -66.62% 15.72% 26.05% -59.95% -1745.11% -108.88% 42.36% -2773.00% -109.61% -64.17% 103.38% -25.28% 32.74% -4.54% 37.37% 10.48% -4.97% -21.72% 10.16% 12.11% -13.62% -275.07% -116.14%    
      net income margin %
    		Infinity% Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -52959.09% NaN% NaN% 
      other comprehensive income
    		                                               
      net unrealized loss on marketable securities
    		-2,225,000   -153,000 -139,000   -46,000 -105,000                                       
      foreign currency translation adjustment
    		-28,000 -13,000 14,000 12,000 4,000 -750 -1,000 -1,000 -1,000 -250 -1,000 -16,000 16,000 -500 -1,000 1,000 -2,000                               
      total comprehensive income
    		29,125,000 43,413,000 26,288,000                                             
      less: undistributed earnings attributable to participating securities
    		-1,000                                               
      net income attributable to common stockholders - basic and diluted
    		31,377,000                                               
      net income per share
    		0.6 0.85 0.49                                   -0.213 -0.41         
      weighted-average common shares outstanding - basic
    		52,091,047 50,817,586 53,328,094                                             
      weighted-average common shares outstanding - diluted
    		53,066,971 52,384,886 54,921,916                                             
      net unrealized gain on marketable securities
    		 68,000 261,000   -537,000 1,049,000                                         
      revenue
    		                                            22,000   
      yoy
    		                                               
      qoq
    		                                               
      total revenue
    		   32,657,000                                  283,788 329,000   241,472 247,000 97,000    
      total comprehensive loss
    		   -4,849,000 -43,908,000 -56,516,000 -75,568,000 -21,901,000 -21,504,000 -6,923,250 -10,862,000 -8,491,000 -8,340,000 -4,645,750 -6,133,000 -6,724,000 -5,726,000                               
      net loss per common share, basic and diluted
    		   -90 -950 -1,300 -1,830 -570 -590 290 -950 -810 -880 -270 -760 -60 -70 -87.5 -100 -140 -110   -160 -130   -310 -220 30 -130 -380 -190 1,188.25 -350 -70 -110           
      weighted-average common shares outstanding used to calculate basic and diluted net loss per common share
    		   50,483,281,000 46,178,793,000 40,175,926,000 41,879,025,000 38,631,565,000 36,208,371,000 16,492,132,000 11,436,748,000 10,423,598,000 9,447,350,000 8,397,088,000 8,093,033,000 120,088,816,000 80,020,677,000 79,770,334,000 79,791,075,000 79,747,506,000 79,694,781,000 62,620,227,000  46,236,209,000 44,679,858,000 34,142,478,000  31,776,951,000 31,756,120,000 20,975,479,000 21,432,482,000 20,345,437,000 19,530,311,000 8,977,795 10,766,608,000 53,060,868,000 26,853,433,000 15,507,484 15,761,530  14,796,119,000 9,425,880 10,040,079,000  6,965,483,000 1,270,033 535,685,000 
      general and administrative
    		     37,303,000 49,197,000 10,889,000 8,472,000 4,140,000 3,318,000 3,169,000 2,854,000 2,402,000 2,332,000 2,467,000 2,643,000 2,596,000 2,767,000 2,464,000 2,979,000 2,251,000 2,256,000 2,248,000 2,003,000 1,608,000 1,615,000 1,695,000 2,012,000 1,365,000 1,558,000 1,766,000 1,867,000 1,684,650 1,707,000 2,195,000 1,158,000 1,890,203 1,398,000 1,509,000 1,939,000 1,708,821 1,714,000 1,432,000 1,292,000 1,080,154 522,000 
      change in fair value of warrants liabilities
    		         -163,000 -653,000 1,000  7,750 2,000 2,000 27,000 139,000 112,000 56,000 201,000 5,105,000 -689,000 3,808,000 3,413,000 -7,894,000 7,116,000 -4,267,000 -1,919,000 2,071,000 1,543,000 -3,834,000 212,000     344,117 200,000 -47,000 1,170,000 661,140 73,000 4,925,000 -6,174,000   
      other comprehensive loss
    		                                               
      loss from minority interest investment
    		                          -123,000 -165,000 -190,000                   
      net income per common share:
    		                                               
      basic
    		                     -95 -110   -127.5 30             -230    250    
      diluted
    		                     -95 -110   -132.5 -190             -230    250    
      weighted-average common shares outstanding used in per-share calculation:
    		                                               
      basic
    		                      79,583,254,000    31,793,292,000             15,528,922,000    7,517,794,000    
      diluted
    		                      79,583,254,000    32,443,647,000             15,528,922,000    7,630,644,000    
      cease-use income
    		                               3,000 3,000               
      income from continuing operations
    		                         -4,037,250 889,000                     
      loss from discontinued operations
    		                               -423,000 -514,000               
      income per common share from continuing operations:
    		                                               
      basic
    		                         -127.5 30                     
      diluted
    		                         -132.5 -190                     
      loss per common share from discontinued operations:
    		                                               
      basic
    		                                               
      diluted
    		                                               
      loss from continuing operations
    		                           -10,008,000 -7,030,000 393,000 -2,309,000 -7,214,000 -3,241,000 -4,480,850 -2,551,000             
      loss per common share from continuing operations, basic and diluted
    		                           -310 -220 40 -110 -360 -170 848.65 -240             
      loss per common share from discontinued operations, basic and diluted
    		                              -20 -20 -20               
      sales and marketing
    		                                 -269   114,000 173,591 342,000 577,000 538,000 498,470 467,000 506,000 260,000 156,359 84,000 
      interest and other income
    		                             18,750 26,000 30,000 19,000 -155,250 138,000 -29,000 -677,000 300,500 191,000 -63,000 1,074,000       
      loss on sale of assets
    		                                 -52,000 -208,000             
      total
    		                             -130,000 -427,000   -762,250 -1,235,000             
      total expenses
    		                                 1,743,000 2,689,000 3,169,000 2,266,000 3,017,597 2,871,000 3,413,000 4,249,000 3,491,535 3,374,000 3,119,000 2,430,000 1,845,729 1,323,000 
      change in fair value of warrants liabilities income
    		                                 -7,250 130,000 -32,000 -69,000           
      cease-use expense
    		                                 750 4,000  -7,000 251   -94,000       
      other expense
    		                                 -150,500   -602,000 20,233 -9,000 -16,000 -2,000 -565 -183,000     
      loss from discontinued operations:
    		                                               
      operating
    		                                 -80 -90             
      cost of product revenue
    		                                   42,000 209,000 321,750 399,000 428,000 461,000 24,000 56,000 22,000    
      gross loss
    		                                   -41,000            
      expenses
    		                                               
      net income from continuing operations
    		                                   -3,239,000            
      net loss from discontinued operations
    		                                   -727,000            
      net loss per common share from continuing operations, basic and diluted
    		                                   -60            
      net loss per common share from discontinued operations, basic and diluted
    		                                   -10            
      gross profit
    		                                    56,000 61,482 -70,000 -37,000 -14,000 -15,211 191,000 75,000 4,000   
      yoy
    		                                    -500.00% -504.19% -136.65% -149.33% -450.00%       
      qoq
    		                                    -8.92% -187.83% 89.19% 164.29% -7.96% -107.96% 154.67% 1775.00%    
      gross margin %
    		NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% Infinity% Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% Infinity% 18.18% NaN% NaN% 
      government grant revenue
    		                                         -83 155,000 65,000    
      inducement charge for series c warrants
    		                                         625   -3,050,000   
      loss on extinguishment of convertible preferred stock
    		                                     7,302,172 -3,651,000         
      net loss attributable to common stockholders
    		                                     -3,275,750 -6,401,000         
      weighted-average common shares outstanding used to calculate net income per common share:
    		                                               
      basic
    		                      79,583,254,000    31,793,292,000             15,528,922,000    7,517,794,000    
      diluted
    		                      79,583,254,000    32,443,647,000             15,528,922,000    7,630,644,000    
      basic and diluted net loss per common share
    		                                        -220 1,598.31 -330  -1,670 11,229.08 -4,470 
      cost of revenue
    		                                            18,000   
      interest
    		                                            -1,000 -452,750 -752,000 
      net loss and comprehensive loss
    		                                             -1,504,750 -2,393,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 
                                                     
        assets
      		                                               
        current assets
      		                                               
        cash and cash equivalents
      		133,026,000 70,106,000 246,662,000 76,497,000 81,331,000 87,928,000 48,413,000 57,024,000 42,847,000 169,681,000 52,437,000 19,368,000 7,874,000 14,602,000 19,751,000 24,065,000 28,974,000 21,304,000 28,185,000 33,596,000 41,607,000 49,224,000 56,137,000 62,499,000 15,070,000 20,733,000 11,225,000 15,503,000 19,402,000 23,099,000 10,239,000 12,593,000 14,866,000 17,099,507 5,647,000 7,547,000 10,539,000 2,725,996 5,415,000 2,502,000 6,492,000 5,494,523 4,720,000 7,530,000 9,529,000 7,956,710 64,000 
        marketable securities
      		122,573,000 235,366,000 252,272,000 210,344,000 208,619,000 203,509,000 208,363,000 209,099,000                                        
        accounts receivable
      		47,139,000 28,208,000 25,506,000 24,624,000                                3,000 110,000 133,337 137,000 288,000 187,000 156,127 94,000 12,000 8,000  37,000 
        inventory
      		17,308,000 15,024,000 6,674,000 2,355,000                                164,000 855,000 660,391 703,000 774,000 653,000 551,008 376,000 277,000 206,000 109,336  
        prepaid expenses and other current assets
      		6,330,000 7,110,000 3,739,000 2,969,000 18,965,000 2,452,000 1,423,000 1,379,000 1,596,000 1,677,000 1,222,000 1,130,000 1,253,000 1,045,000 821,000 824,000 1,004,000 1,118,000 702,000 948,000 921,000 1,019,000 348,000 505,000 572,000 411,000 375,000 471,000 603,000 529,000 327,000 248,000 423,000 342,927 145,000 246,000 261,000 246,570 217,000 157,000 216,000 167,642 225,000 311,000 260,000 252,272 186,000 
        total current assets
      		326,376,000 355,814,000 534,853,000 316,789,000 308,915,000 293,889,000 258,199,000 267,502,000 151,223,000 171,358,000 53,659,000 20,498,000 9,127,000 15,647,000 20,572,000 24,889,000 29,978,000 22,422,000 28,887,000 34,544,000 42,528,000 50,243,000 56,485,000 63,004,000 15,642,000 21,144,000 11,609,000 16,615,000 20,865,000 24,670,000 11,413,000 13,311,000 15,808,000 17,993,807 6,390,000 10,318,000 11,800,000 3,801,294 6,507,000 3,756,000 7,583,000 6,404,300 5,526,000 8,165,000 10,023,000 8,338,318 307,000 
        long-term assets
      		                                               
        property and equipment
      		202,000 185,000 150,000 166,000 173,000 186,000 196,000 19,000 27,000 12,000 15,000 19,000 22,000 26,000 23,000 28,000 27,000 33,000 26,000 27,000 20,000 19,000 20,000 17,000 19,000 22,000 46,000 22,000 19,000 12,000 14,000 13,000 17,000 22,885 55,000 53,000 93,000 102,560 116,000 118,000 121,000 85,745 98,000 43,000 44,000 57,607 36,000 
        operating lease right-of-use assets
      		3,891,000 2,191,000 2,314,000 2,434,000 2,603,000 2,798,000 2,992,000 268,000 338,000 407,000 474,000 541,000 53,000 131,000 206,000 279,000 350,000 421,000 489,000 558,000 50,000 124,000 195,000 265,000 332,000 398,000                      
        intangible assets
      		4,374,000 4,861,000 5,347,000 5,832,000 6,318,000 6,805,000 7,291,000 7,777,000 8,263,000 8,749,000 9,235,000 9,721,000 10,207,000 10,693,000 11,178,000 11,665,000 12,151,000 12,637,000 13,123,000 13,609,000 14,095,000 14,581,000 15,067,000 15,553,000 16,039,000 16,525,000 17,011,000 17,497,000 17,983,000 18,469,000 18,955,000 19,441,000 19,927,000 20,413,056              
        long-term marketable securities
      		273,382,000 200,616,000 57,148,000 7,002,000  27,211,000 27,945,000 28,482,000                                        
        other long-term assets
      		163,000 163,000 83,000 83,000 83,000 83,000 83,000 83,000 165,000 165,000 165,000 165,000 126,000    40,000 40,000 40,000 40,000     59,000 59,000 59,000                     
        total assets
      		608,388,000 563,830,000 599,895,000 332,306,000 318,092,000 330,972,000 296,706,000 304,131,000 168,837,000 180,691,000 63,548,000 30,944,000 19,535,000 26,497,000 31,979,000 36,861,000 42,546,000 35,553,000 42,565,000 48,778,000 56,706,000 64,982,000 71,784,000 78,859,000 32,113,000 38,172,000 28,725,000 34,134,000 38,867,000 43,151,000 30,835,000 33,344,000 36,331,000 39,021,665 26,382,000 30,381,000 33,865,000 5,564,852 8,309,000 5,535,000 9,390,000 8,201,195 7,288,000 8,770,000 10,067,000 8,395,925 1,696,000 
        liabilities and stockholders’ equity
      		                                               
        current liabilities
      		                                               
        accounts payable
      		12,386,000 12,435,000 8,145,000 6,216,000 5,483,000 8,882,000 6,243,000 3,716,000 8,022,000 3,149,000 3,216,000 3,442,000 2,778,000 1,777,000 2,324,000 2,406,000 2,411,000 3,254,000 3,858,000 3,348,000 4,669,000 3,489,000 3,213,000 3,657,000 3,480,000 1,995,000 1,735,000 1,740,000 1,258,000 934,000 1,245,000 981,000 1,133,000 633,104 642,000 1,029,000 935,000 537,891 862,000 957,000 1,262,000 695,056 953,000 989,000 621,000 986,799 1,238,000 
        accrued compensation
      		5,723,000 9,677,000 7,248,000 6,267,000 4,277,000 4,776,000 3,408,000 2,149,000 1,226,000 3,135,000 1,498,000 1,165,000 721,000 1,675,000 1,282,000 932,000 598,000 728,000 809,000 652,000 411,000 1,005,000 756,000 520,000 338,000 283,000                      
        operating lease liabilities
      		1,163,000 726,000 697,000 676,000 597,000 526,000 448,000 296,000 310,000 273,000   39,000 155,000 239,000 337,000 344,000 282,000 290,000 180,000 57,000 139,000 220,000 298,000 315,000 305,000                      
        contingent liability for essentialis purchase price
      		13,846,000 20,327,000 19,473,000 18,859,000 17,758,000 14,791,000 14,464,000 13,587,000 11,950,000 11,549,000 10,468,000 9,447,000 9,134,000 8,835,000 9,437,000 9,305,000 8,689,000 9,547,000 12,876,000 12,325,000 9,291,000 10,278,000 10,138,000 9,364,000 6,522,000 5,938,000 6,066,000 6,038,000 5,855,000 5,649,000 5,671,000 5,443,000 5,510,000 5,081,840              
        other current liabilities
      		24,931,000 18,198,000 17,163,000 5,512,000 3,127,000 2,737,000 3,101,000 1,126,000 1,511,000 1,555,000 848,000 513,000 692,000 484,000 671,000 415,000 439,000 323,000 492,000 255,000 232,000 196,000 408,000 444,000 308,000 382,000                      
        total current liabilities
      		58,049,000 61,363,000 33,253,000 20,943,000 15,731,000 18,747,000 14,962,000 9,150,000 13,464,000 11,505,000 28,993,000 8,798,000 7,761,000 7,313,000 7,342,000 7,246,000 7,313,000 8,007,000 9,042,000 8,362,000 9,509,000 8,618,000 7,996,000 8,363,000 7,287,000 4,964,000 3,454,000 2,855,000 2,250,000 1,877,000 2,508,000 1,945,000 1,942,000 1,732,769 1,731,000 2,122,000 2,172,000 1,707,378 1,777,000 1,901,000 2,579,000 3,192,735 6,028,000 13,349,000 1,059,000 1,289,785 1,596,000 
        long-term liabilities
      		                                               
        long-term debt
      		49,871,000 49,863,000 49,854,000 49,845,000 49,836,000 49,828,000                                          
        long-term lease liabilities
      		3,243,000 1,964,000 2,112,000 2,248,000 2,361,000 2,472,000 2,581,000  37,000 130,000       79,000 175,000                              
        other long-term liabilities
      		1,425,000 525,000 398,000 271,000 145,000 21,000                   60,000 147,000 38,000        1,132,000 1,132,000 1,201,000  196,000 200,000 200,000       
        total liabilities
      		112,588,000 113,715,000 105,090,000 92,166,000 85,831,000 85,859,000 32,007,000 23,374,000 25,451,000 23,184,000 40,328,000 18,518,000 16,896,000 16,149,000 16,779,000 16,553,000 16,085,000 17,760,000 22,362,000 21,341,000 19,138,000 19,435,000 23,778,000 22,682,000 22,632,000 23,225,000 13,840,000 20,291,000 15,236,000 12,738,000 16,630,000 17,507,000 13,312,000 12,486,757 3,172,000 3,693,000 3,721,000 2,129,655     8,579,000 16,402,000 21,370,000   
        commitments and contingencies
      		                                               
        stockholders’ equity
      		                                               
        preferred stock, 0.001 par value...
      		                                               
        common stock, 0.001 par value...
      		52,000 52,000 54,000 50,000 49,000 46,000 41,000 38,000 33,000 32,000 15,000 10,000 8,000 8,000 8,000 120,000 120,000 80,000 80,000 80,000 80,000 80,000 80,000 80,000 45,000 45,000 32,000 32,000 32,000 32,000 21,000 21,000 20,000 19,239 10,000 48,000 47,000 16,786 15,000 15,000 15,000 14,018 12,000 8,000 7,000 6,769 1,000 
        additional paid-in-capital
      		897,578,000 881,018,000 969,119,000 740,746,000 728,019,000 696,966,000 660,041,000 600,534,000 441,267,000 433,885,000 288,320,000 266,669,000 248,393,000 247,762,000 247,130,000 245,993,000 245,422,000 231,068,000 230,650,000 229,744,000 228,887,000 227,912,000 227,519,000 227,145,000 173,100,000 172,708,000 158,034,000 157,881,000 157,661,000 157,413,000 141,479,000 141,187,000 140,733,000 140,494,976 132,154,000 131,807,000 131,296,000 101,730,285 101,395,000 95,543,000 95,255,000 89,456,466 82,099,000 72,469,000 70,679,000 60,635,664 20,741,000 
        accumulated other comprehensive income
      		-1,838,000 415,000 360,000 85,000         16,000                                   
        accumulated deficit
      		-399,992,000 -431,370,000 -474,728,000 -500,741,000 -496,033,000 -452,260,000 -396,278,000 -319,662,000 -297,808,000 -276,410,000 -265,114,000 -254,253,000 -245,778,000 -237,422,000 -231,936,000 -225,804,000 -219,079,000 -213,355,000 -210,527,000 -202,387,000 -191,399,000 -182,445,000 -179,593,000 -171,048,000 -163,664,000 -157,806,000 -143,181,000 -144,070,000 -134,062,000 -127,032,000 -127,295,000 -125,371,000 -117,734,000 -113,979,312 -108,954,000 -105,167,000 -101,199,000 -98,311,887 -95,698,000 -92,948,000 -89,436,000 -86,246,673 -83,402,000 -80,109,000 -81,989,000 -70,975,024 -63,120,000 
        total stockholders’ equity
      		495,800,000 450,115,000 494,805,000 240,140,000 232,261,000 245,113,000 264,699,000 280,757,000 143,386,000 157,507,000 23,220,000 12,426,000 2,639,000 10,348,000 15,200,000 20,308,000 26,461,000 17,793,000 20,203,000 27,437,000 37,568,000 45,547,000 48,006,000 56,177,000 9,481,000 14,947,000 14,885,000 13,843,000 23,631,000 30,413,000 14,205,000 15,837,000 23,019,000 26,534,908 23,210,000 26,688,000 30,144,000 3,435,197 5,712,000 2,610,000 5,834,000 3,223,816      
        total liabilities and stockholders’ equity
      		608,388,000 563,830,000 599,895,000 332,306,000 318,092,000 330,972,000 296,706,000 304,131,000 168,837,000 180,691,000 63,548,000 30,944,000 19,535,000 26,497,000 31,979,000 36,861,000 42,546,000 35,553,000 42,565,000 48,778,000 56,706,000 64,982,000 71,784,000 78,859,000 32,113,000 38,172,000 28,725,000 34,134,000 38,867,000 43,151,000 30,835,000 33,344,000 36,331,000 39,021,665 26,382,000 30,381,000 33,865,000 5,564,852 8,309,000 5,535,000 9,390,000 8,201,195      
        accrued clinical trial site costs
      		   1,863,000 1,824,000 1,826,000 1,762,000 1,863,000 2,395,000 3,393,000 3,237,000 3,466,000 3,531,000 3,222,000 2,826,000 3,156,000 3,521,000 3,420,000 3,593,000 3,927,000 4,140,000 3,789,000 3,399,000 3,444,000 2,846,000 1,999,000                      
        accrued interest payable
      		   409,000 423,000                                           
        accumulated other comprehensive gain
      		    226,000 361,000 895,000                                         
        common stock purchase liability
      		       637,000   19,938,000                                     
        accumulated other comprehensive loss
      		       -153,000 -106,000  -1,000    -2,000 -1,000 -2,000                               
        short-term investments
      		        106,780,000                                       
        long-term investments
      		        8,821,000                                       
        2018 pipe warrant liability
      		          653,000  1,000 1,000  2,000 4,000 31,000 170,000 282,000 338,000 539,000 867,000 725,000 1,107,000 1,354,000 590,000 1,145,000 784,000 600,000                  
        operating lease liabilities - current
      		          256,000 212,000                                    
        operating lease liabilities - noncurrent
      		          214,000 273,000                                    
        finance lease right-of-use assets
      		                    13,000 15,000 17,000 20,000 22,000 24,000                      
        operating lease liabilities, net of current
      		                  274,000 372,000                            
        2017 pipe warrant liability
      		                      4,777,000 4,230,000 7,656,000 10,822,000 3,667,000 10,202,000 6,274,000 4,563,000 6,641,000 8,036,000 4,927,000 5,076,000              
        due from related party
      		                          9,000 18,000 72,000 64,000                  
        minority interest investment in former subsidiary
      		                           623,000 788,000 978,000                  
        series a warrant liability
      		                          25,000 51,000 73,000 49,000 58,000 1,015,000 291,000 351,713 289,000 415,000 291,000 194,048 509,000 631,000 558,000 1,212,803 1,819,000 2,159,000 3,582,000   
        preferred stock, .001 par value...
      		                                               
        series b convertible preferred stock, 13,780 shares designated at december 31, 2019 and december 31, 2018; zero shares issued and outstanding at december 31, 2019 and at december 31, 2018. liquidation value of zero.
      		                                               
        accrued compensation and other current liabilities
      		                          1,719,000 1,115,000 992,000 943,000 1,153,000 862,000 721,000 973,054 976,000 879,000 1,237,000 1,169,487 915,000 944,000 1,317,000 1,632,679 1,224,000 1,223,000 438,000 201,457  
        series b convertible preferred stock, 13,780 shares designated at september 30, 2019 and december 31, 2018; zero shares issued and outstanding at september 30, 2019 and at december 31, 2018. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 shares designated at june 30, 2019 and december 31, 2018; zero shares issued and outstanding at june 30, 2019 and at december 31, 2018. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 shares designated at march 31, 2019 and december 31, 2018; zero shares issued and outstanding at march 31, 2019 and at december 31, 2018. liquidation value of zero.
      		                                               
        restricted cash
      		                                35,000 35,000 35,000 35,000 35,000 35,000 35,000 35,000 35,000 35,000 111,000 35,000 20,000 20,000 20,000 
        current assets held for sale
      		                              847,000 470,000 484,000 516,373 563,000 2,323,000            
        other assets
      		                               126,000 126,000 125,530 126,000 126,000 126,000 125,530 126,000 76,000 76,000 76,340      
        long-term assets held for sale
      		                              453,000 453,000 453,000 466,387 458,000             
        current liabilities held for sale
      		                              110,000 102,000 88,000 126,611 113,000 214,000            
        series c warrant liability
      		                              2,000 5,000 4,000 5,880 20,000 24,000 57,000 85,490 115,000 193,000 219,000 462,437 581,000 894,000 2,549,000   
        other liabilities
      		                               13,000 13,000 13,163    142,739    109,404 151,000     
        long-term liabilities held for sale
      		                              1,750,000 1,050,000 625,000 225,392              
        series b convertible preferred stock, 13,780 shares designated at december 31, 2018 and december 31, 2017; zero and 4,571 shares issued and outstanding at december 31, 2018 and at december 31, 2017, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 are designated at september 30, 2018 and december 31, 2017; nil and 4,571 shares issued and outstanding at september 30, 2018 and december 31, 2017, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 are designated at june 30, 2018 and december 31, 2017; nil and 4,571 shares issued and outstanding at june 30, 2018 and december 31, 2017, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 are designated at march 31, 2018 and december 31, 2017; 3,571 and 4,571 shares issued and outstanding at march 31, 2018 and december 31, 2017, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 shares designated at december 31, 2017, and december 31, 2016; 4,571 and 12,780 shares issued and outstanding at december 31, 2017, and at december 31, 2016, respectively. liquidation value of zero.
      		                                 5              
        other intangible assets
      		                                  19,353,000 19,884,000 21,128,000 817,465 842,000 867,000 892,000 916,807 946,000     
        series b convertible preferred stock, 13,780 are designated at september 30, 2017 and december 31, 2016; 10,049 and 12,780 shares issued and outstanding at september 30, 2017 and at december 31, 2016, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 are designated at june 30, 2017 and december 31, 2016; 12,179 and 12,780 shares issued and outstanding at june 30, 2017 and at december 31, 2016, respectively. liquidation value of zero.
      		                                               
        goodwill
      		                                    718,000 718,003 718,000 718,000 718,000 718,003 718,000     
        series b convertible preferred stock, 13,780 are designated at march 31, 2017 and december 31, 2016; 12,179 and 12,780 shares issued and outstanding at march 31, 2017 and at december 31, 2016, respectively. liquidation value of zero.
      		                                               
        series b warrant liability
      		                                         865,000 3,851,000 11,025,000 14,180,000 17,438,731  
        series a convertible preferred stock, 10,000 shares designated; zero and 4,555 issued and outstanding at december 31, 2016 and december 31, 2015, respectively. liquidation value of zero.
      		                                               
        series b convertible preferred stock, 13,780 and zero shares designated at december 31, 2016 and december 31, 2015, respectively; 12,780 and zero shares issued and outstanding at december 31, 2016 and at december 31, 2015, respectively. liquidation value of zero.
      		                                     13          
        series a convertible preferred stock, 10,000 shares designated; zero and 4,555 issued and outstanding at september 30, 2016 and december 31, 2015, respectively
      		                                               
        series b convertible preferred stock, 13,780 and zero shares designated at september 30, 2016 and december 31, 2015, respectively; 13,780 and zero shares issued and outstanding at september 30, 2016 and at december 31, 2015, respectively
      		                                               
        series a convertible preferred stock, 0.001 par value...
      		                                         5     1,500,000 
        line of credit and accrued interest
      		                                             101,529  
        liabilities and stockholders’ deficit
      		                                               
        total long-term liabilities
      		                                          2,551,000 3,053,000 20,311,000   
        stockholders’ deficit
      		                                               
        total stockholders’ deficit
      		                                          -1,291,000 -7,632,000 -11,303,000 -10,332,591 -42,378,000 
        total liabilities and stockholders’ deficit
      		                                          7,288,000 8,770,000 10,067,000 8,395,925 1,696,000 
        patent
      		                                           562,000    
        common stock issuable
      		                                           112,000    
        liabilities, convertible preferred stock and stockholders’ deficit
      		                                               
        convertible promissory notes and accrued interest
      		                                               
        convertible preferred stock warrant liability
      		                                              3,066,000 
        commitments
      		                                               
        convertible preferred stock
      		                                               
        series b convertible preferred stock, 0.001 par value...
      		                                              6,863,000 
        series c convertible preferred stock, 0.001 par value...
      		                                              15,445,000 
        deferred offering costs
      		                                              1,353,000 
        accrued liabilities
      		                                              358,000 
        convertible promissory notes and accrued interest, net of discounts
      		                                              15,604,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 
                                                      
          cash flows from operating activities:
        		                                              
          net income
        		31,378,000                                              
          adjustments to reconcile net income to net cash from operating activities:
        		                                              
          depreciation and amortization
        		514,000 509,000 502,000 502,000 504,000 503,000 500,000 494,000 490,000 489,000 490,000 489,000 490,000 488,000 492,000 492,000 492,000 492,000 492,000 490,000 489,000 488,000 489,000 488,000 489,000 490,000 490,000 489,000 489,000 490,000 490,000 491,000 492,000 582,271 459,000 419,000 151,000 37,640 39,000 35,000 20,000 60,228 17,000 16,000 15,000 8,516 
          accretion of premium/discount on marketable securities
        		-221,000 -1,192,000 -371,000 -974,000 -980,000 -1,400,000 -1,909,000                                        
          non-cash lease expense
        		149,000 123,000 120,000 169,000 195,000  111,000 70,000 69,000  67,000 109,000 78,000  73,000 71,000 71,000  69,000 75,000 76,000                          
          amortization of debt issuance costs
        		8,000 9,000 9,000 9,000 8,000                                          
          stock-based compensation expense
        		16,056,000 11,471,000 9,998,000 9,698,000 14,679,000 29,755,000 56,598,000 7,160,000 6,445,000 1,909,000 2,201,000 1,204,000 631,000 632,000 683,000 571,000 644,000 418,000 906,000 857,000 1,095,000 393,000 374,000 341,000 392,000 295,000 153,000 175,000 202,000 257,000 211,000 179,000 341,000 25,031 227,000 443,000 185,000 311,270 206,000 218,000 136,000 196,369 144,000 201,000 401,000 324,435 
          change in fair value of contingent consideration
        		484,000 854,000 614,000 1,101,000 2,967,000 327,000 877,000 1,637,000 401,000 1,081,000 1,021,000 313,000 299,000 -602,000 132,000 616,000 -858,000 -3,329,000 551,000 3,034,000 -987,000 140,000 774,000 2,842,000 584,000 -128,000 28,000 183,000 206,000 -22,000 228,000 -67,000 428,000    5,000  8,000 8,000 19,000      
          other non-cash reconciling items
        		-28,000 -13,000 14,000 12,000 4,000  -1,000 -1,000 -1,000    16,000  -1,000 1,000 -2,000                              
          change in operating assets and liabilities:
        		                                              
          accounts receivable
        		-18,931,000 -2,702,000 -882,000                                  23,000 3,790 151,000 -101,000 -31,000 -62,127 -82,000 -4,000 -8,000 37,605 
          inventory
        		-1,831,000 -8,020,000 -3,916,000                                 32,000 -195,000 42,617 71,000 -121,000 -102,000      
          prepaid expenses, other current assets and other assets
        		780,000 -3,451,000 -948,000 3,077,000 -3,416,000 -1,029,000 -101,000 299,000 81,000 -660,000 113,000 44,000 -334,000 -224,000 3,000 220,000 114,000   -15,000 98,000 -671,000 157,000 126,000 -161,000                      
          accounts payable
        		-2,970,000 4,286,000 1,929,000 733,000 -3,336,000 2,578,000 2,527,000 -4,298,000 4,865,000 34,000 -341,000 678,000 1,001,000 -547,000 -82,000 198,000 -1,046,000 -604,000 522,000 -1,333,000 1,180,000 279,000 -404,000 134,000 1,485,000 260,000 -5,000 482,000 324,000 -363,000 264,000 -61,000 409,000 -41,370 -38,000 445,000 -175,000 -324,163 -159,000 -293,000 627,000 -330,055 141,000 202,000 199,000 250,897 
          accrued compensation
        		-3,954,000 2,429,000 981,000 1,990,000 -499,000 1,368,000 1,259,000 923,000 -1,909,000 1,637,000 333,000 444,000 -954,000 393,000 350,000 334,000 -130,000 -81,000 157,000 241,000 -594,000 249,000 236,000 182,000 55,000                      
          operating lease liabilities
        		-133,000 -119,000 -115,000 -34,000 -40,000 -31,000 -45,000 -51,000 -56,000 -67,000 -15,000 -111,000 -116,000 -84,000 -98,000 -86,000 -34,000 -107,000 12,000 -86,000 -82,000 -81,000 -217,000 -17,000 10,000                      
          essentialis acquisition milestone payments
        		-2,954,000                                              
          other liabilities
        		7,633,000 1,162,000 9,543,000 2,497,000 937,000 -341,000 1,975,000 -385,000 -44,000 805,000 237,000 -179,000 208,000 -187,000 256,000 55,000 37,000 -164,000 237,000 21,000 41,000 -170,000 255,000 -105,000 -157,000                      
          net cash from operating activities
        		25,980,000 48,704,000 43,454,000 -12,608,000 -32,752,000 -23,991,000 -14,926,000 -17,651,000 -12,528,000 -6,314,000 -6,332,000 -5,566,000 -6,728,000 -5,143,000 -4,656,000 -4,620,000 -6,362,000 -6,863,000 -5,406,000 -8,013,000 -7,488,000 -6,867,000 -6,164,000 -6,534,000 -5,659,000 -5,076,000 -4,719,000 -3,893,000 -3,687,000 -3,736,000 -2,677,000 -2,750,000 -2,520,000 -2,731,958 -2,271,000 -2,764,000 -2,183,000 -2,687,980 -2,786,000 -4,040,000 -3,984,000 -3,378,330 -2,861,000 -2,251,000 -1,809,000 -1,556,362 
          capital expenditures
        		-36,000 -58,000 -1,000 -9,000 -5,000 -8,000 -191,000 -8,000 -3,000 0 0 0 0 -6,000 0 0  -13,000 -5,000 0 -4,000 -6,000 0 0  -5,000 0 -6,000 -10,000 -2,000 -5,000 0 0 1,431 0 0 -4,000 320 0 -20,000 -19,000 -7,777 -32,000 -15,000 -1,000 0 
          free cash flows
        		25,944,000 48,646,000 43,453,000 -12,617,000 -32,757,000 -23,999,000 -15,117,000 -17,659,000 -12,531,000 -6,314,000 -6,332,000 -5,566,000 -6,728,000 -5,149,000 -4,656,000 -4,620,000  -6,876,000 -5,411,000 -8,013,000 -7,492,000 -6,873,000 -6,164,000 -6,534,000  -5,081,000 -4,719,000 -3,899,000 -3,697,000 -3,738,000 -2,682,000 -2,750,000 -2,520,000 -2,730,527 -2,271,000 -2,764,000 -2,187,000 -2,687,660 -2,786,000 -4,060,000 -4,003,000 -3,386,107 -2,893,000 -2,266,000 -1,810,000 -1,556,362 
          cash flows from investing activities:
        		                                              
          purchases of property and equipment
        		-40,000 -58,000 -1,000 -9,000 -5,000 -8,000 -191,000 -8,000 -11,000     -6,000 0   -13,000 -5,000 0 -4,000 -4,000    -5,000 0 -6,000 -10,000 -2,000 -5,000                
          purchases of marketable securities
        		-101,268,000 -187,840,000 -163,172,000 -59,406,000 -45,358,000 -47,549,000 -47,769,000 -145,913,000 -115,233,000                                      
          maturities of marketable securities
        		139,291,000 62,538,000 71,730,000 51,500,000 68,300,000 54,000,000 52,000,000                                        
          net cash from investing activities
        		37,983,000 -125,360,000 -91,443,000 -7,915,000 22,937,000 6,443,000 4,040,000 -120,921,000 -115,244,000     -6,000 0   -13,000 -5,000 0 -4,000 -4,000    103,000 441,000 -6,000 -10,000     239,782 371,000 -228,000 -4,000 320 0 -20,000 -19,000 -31,777 -1,258,000 -30,000 -1,000  
          cash flows from financing activities:
        		                                              
          payment for repurchase of common stock
        		-4,000                                              
          payment of debt issuance costs
        		 0 0 0 -62,000                                          
          proceeds from exercise of common stock warrants
        		  0 2,176,000 3,011,000    923,000                                      
          proceeds from exercise of stock options
        		52,000 954,000 2,255,000 13,724,000 269,000 -1,000 765,000 537,000 15,000                                      
          tax withholding payments for net share-settled equity awards
        		-1,000 -708,000 0           0 0 0 -16,000 0 0 0 -120,000                          
          net cash from financing activities
        		-1,043,000 -99,900,000 218,154,000 15,689,000 3,218,000 57,063,000 2,275,000 152,749,000 938,000 123,558,000 39,401,000   0 342,000 -282,000 14,032,000 -5,000 0 2,000 -125,000 -42,000 -195,000 53,963,000 -4,000     16,302,000 700,000 537,000 288,000 13,944,687 0 0 10,000,000 -867 5,699,000 70,000 5,000,000 4,184,920 1,309,000 282,000 3,382,000 9,479,985 
          net increase in cash and cash equivalents
        		62,920,000 -176,556,000    39,515,000 -8,611,000   117,244,000 33,069,000 11,494,000 -6,728,000   -4,909,000 7,670,000 -6,881,000 -5,411,000   -6,913,000 -6,362,000            -1,900,000 -2,992,000 7,813,000    997,000 774,813 -2,810,000 -1,999,000 1,572,000  
          cash and cash equivalents, beginning of period
        		70,106,000 0 0 0 87,928,000 0 0 0 169,681,000 0 0 0 14,602,000 0 0 0 21,304,000 0 0 0 49,224,000 0 0 0 20,733,000         -4 0 0 2,726,000 -477 0 0 5,495,000 -290 0 0 7,957,000 -230 
          cash and cash equivalents, end of period
        		133,026,000 -176,556,000 170,165,000 -4,834,000 81,331,000 39,515,000 -8,611,000 14,177,000 42,847,000 117,244,000 33,069,000 11,494,000 7,874,000 -5,149,000 -4,314,000 -4,909,000 28,974,000 -6,881,000 -5,411,000 -8,011,000 41,607,000 -6,913,000 -6,362,000 47,429,000 15,070,000         11,452,507 -1,900,000 -2,992,000 10,539,000 -2,689,004 2,913,000 -3,990,000 6,492,000 774,523 -2,810,000 -1,999,000 9,529,000 7,892,710 
          supplemental disclosure of non-cash operating and financing information
        		                                              
          cash paid for interest
        		1,155,000 1,218,000 1,256,000 1,255,000 805,000                                          
          operating lease right-of-use assets obtained in exchange for operating lease obligations
        		1,849,000     0    0 0                                    
          purchases of property and equipment included in accounts payable
        		4,000        8,000                                      
          change in fair value of stock warrants
        		          653,000    -2,000 -2,000 -27,000 -139,000 -112,000 -56,000 -201,000 -5,105,000 689,000 -3,808,000 -3,413,000 7,894,000 -7,116,000 4,267,000 1,919,000 -2,071,000 -2,073,000 3,834,000 -212,000              
          proceeds from issuance of debt, net of issuance costs
        		                                              
          proceeds from the sale of common stock, net of issuance costs
        		 0    0 0                                        
          proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
        		                                              
          proceeds from exercise of common stock and pre-funded stock warrants
        		                                              
          common stock repurchase costs included in accounts payable
        		                                              
          non-cash exercise of 2018 pipe warrants
        		                                              
          debt issuance costs included in accounts payable
        		                                              
          net loss
        		  26,013,000 -4,708,000 -43,773,000 -55,982,000 -76,616,000 -21,854,000 -21,398,000 -11,296,000 -10,861,000 -8,475,000 -8,356,000 -5,486,000 -6,132,000 -6,725,000 -5,724,000 -2,828,000 -8,140,000 -10,988,000 -8,954,000 -2,852,000 -8,545,000 -7,384,000 -5,858,000 -14,625,000 889,000 -10,008,000 -7,030,000 263,000 -2,206,000 -7,637,000 -3,755,000 -5,025,425 -3,786,000 -3,969,000 -2,887,000 -2,613,214 -2,750,000 -3,513,000 -3,189,000 -2,844,546 -3,294,000 1,881,000 -11,651,000 -7,855,513 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                              
          proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs
        		                                              
          proceeds received prior to and for the issuance of common stock and pre-funded warrants
        		                                              
          accrued clinical trial site costs
        		   39,000 -2,000 64,000 -101,000 -532,000 -998,000 156,000 -229,000 -65,000 309,000 396,000 -330,000 -365,000 101,000 -173,000 -334,000 -213,000 351,000 390,000 -45,000 598,000 847,000                      
          payment of deferred financing costs
        		                                              
          net decrease in cash and cash equivalents
        		   -4,834,000 -6,597,000    -126,834,000     -5,149,000       -7,617,000    -5,663,000             -2,688,527 2,913,000        
          cash flows from investing activities
        		                                              
          noncash lease expense
        		                     73,000 73,000 69,000 68,000                      
          proceeds from the sale of common stock and common stock warrants, net of costs
        		                                              
          unpaid financing costs included in accounts payable and accrued liabilities
        		                                              
          proceeds received prior to and for the issuance of common stock
        		                                              
          supplemental disclosure of non-cash financing information
        		                                              
          unpaid financing costs included in accounts payable
        		                                              
          accretion of premium/discount on investments
        		        -473,000                                      
          change in fair value of common stock warrants
        		                                  -130,000 90,000 69,000  -200,000 47,000 -1,170,000  -72,000 -4,925,000 6,174,000  
          proceeds from sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
        		                                              
          proceeds from exercise of common stock warrants and pre-funded stock warrants, net of costs
        		                                              
          proceeds from stock option exercises
        		         337,000            0 0                        
          supplemental disclosure of non-cash investing and financing information
        		                                              
          proceeds from sale of common stock and common stock warrants, net of issuance costs
        		                                              
          proceeds from sale of common stock and pre-funded warrants, net of costs
        		              342,000 -282,000 14,048,000                              
          proceeds from exercise of common stock warrants, net of costs
        		                                              
          proceeds from sale of common stock and common stock warrants, net of costs
        		                                              
          unpaid costs for issuing common stock and pre-funded warrants
        		                282,000                              
          gross proceeds from sale of common stock and common stock warrants
        		                                              
          payment of issuance costs
        		                                              
          principal paid on finance lease liabilities
        		                 -5,000 0 2,000 -5,000 -4,000 -5,000 -4,000 -4,000                      
          right-of use assets obtained in exchange for operating lease obligations
        		                                              
          other assets
        		                                              
          supplemental disclosure of non-cash activities
        		                                              
          right-of-use assets obtained in exchange for operating lease obligations
        		                  0                            
          deferred financing costs included in accounts payable
        		                                              
          purchases of property and equipment in accounts payable
        		                     -2,000                         
          prepaid expenses and other current assets
        		                          96,000 132,000 -74,000  47,000 175,000 -80,000              
          other long-term assets
        		                                     810         
          proceeds from sale of common stock, net of costs
        		                      -190,000                        
          purchase of property and equipment in accounts payable
        		                                              
          operating loss of minority interest investment
        		                                              
          due from related party
        		                         9,000 9,000 54,000 -8,000                  
          security deposit on sublease
        		                         0                     
          security deposit received from expired lease
        		                                              
          proceeds from sale of minority interest investment in former subsidiary
        		                         0                     
          supplemental disclosure of non-cash investing information
        		                                              
          operating loss on minority interest investment
        		                          123,000 165,000 190,000                  
          purchases of property and equipment with capital lease obligation
        		                                              
          financing costs in accounts payable and accrued liabilities
        		                                              
          loss from discontinued operations
        		                             -130,000 -427,000 -423,000 -514,000 -544,575 -1,679,000            
          loss from continuing operations
        		                         -14,625,000 889,000 -10,008,000 -7,030,000 393,000 -1,779,000 -7,214,000 -3,241,000 -4,480,850 -2,107,000            
          adjustments to reconcile net loss from continuing operations to net cash from operating activities:
        		                                              
          gain on deconsolidation of former subsidiary
        		                                              
          net cash from continuing operating activities
        		                         -5,076,000 -4,719,000 -3,893,000 -3,687,000 -3,548,000 -2,273,000 -2,468,000 -2,033,000 -2,277,768 -1,122,000            
          net cash from discontinued operating activities
        		                             -188,000 -404,000 -282,000 -487,000  -1,149,000            
          net cash from continuing investing activities
        		                         103,000 441,000 -6,000 -10,000 -2,000 -5,000   15,002 -350,000            
          net cash from discontinued investing activities
        		                                 224,780 721,000            
          net cash from continuing financing activities
        		                                -112,000 13,944,687 0            
          net cash from discontinued financing activities
        		                             0 700,000 425,000 400,000              
          net increase in cash and cash equivalents from continuing operations
        		                                              
          net decrease in cash and cash equivalents from discontinued operations
        		                                              
          supplemental disclosures of non-cash investing and financing information
        		                                              
          accrued liability for cost of issuing common stock
        		                                              
          warrants issued in connection with sale of common stock
        		                                              
          board fees paid with common stock
        		                          0 45,000 46,000 78,000 61,000 54,000 82,000 82,786 82,000 68,000 45,000          
          accrued compensation and other liabilities
        		                                              
          net decrease in cash, cash equivalents and restricted cash from continuing operations
        		                          -4,278,000 -3,899,000 -3,697,000                  
          net increase in cash, cash equivalents and restricted cash from discontinued operations
        		                              296,000                
          net decrease in cash, cash equivalents and restricted cash
        		                          -4,278,000 -3,899,000 -3,697,000                  
          net increase in cash and cash equivalents included in current assets held for sale
        		                              -372,000 -94,000 -2,000              
          cash, cash equivalents and restricted cash, beginning of period
        		                          0 0 23,099,000 0 0 0 17,135,000              
          cash, cash equivalents and restricted cash, end of period
        		                          -4,278,000 -3,899,000 19,402,000 12,860,000 -2,354,000 -2,308,000 14,901,000              
          accrued compensation and other current liabilities
        		                           123,000 49,000 -210,000 278,000 141,000 -252,000 -4,303 119,000 -239,000 46,000 255,808 -30,000 -372,000 -317,000      
          net decrease in cash, cash equivalents and restricted cash from discontinued operations
        		                                -87,000              
          cash paid for the issuance of common stock and common stock warrants
        		                                              
          income tax benefit
        		                                              
          non-cash expense of issuing shares to aspire capital
        		                                  0 0 602,000          
          other long-term liabilities
        		                                 -20,040 0 17,000 -37,000 -40,365 -12,000 -8,000 72,000      
          costs of essentialis acquisition paid
        		                                  -350,000            
          proceeds from issuance of common stock
        		                                 0 0 0 10,000,000          
          proceeds from sale of common stock and common stock warrants
        		                                              
          net increase in cash, cash equivalents and restricted cash from continuing operations
        		                             12,752,000 -2,278,000 -2,357,000 -2,145,000              
          net increase in cash, cash equivalents and restricted cash
        		                             12,392,000 -1,982,000 -2,214,000 -2,232,000              
          issuance of common stock in essentialis acquisition
        		                                  0 -22,000 18,786,000          
          contingent consideration of essentialis acquisition
        		                                  0 0 1,090,000          
          net cash from (used) in investing activities
        		                                              
          costs of essentialis acquisition included in accounts payable
        		                                              
          cash paid for the issuance cost of common stock and common stock warrants
        		                                -112,000              
          contingent cash consideration of essentialis acquisition
        		                                              
          costs of issuing common stock and common stock warrants recorded in accounts payable
        		                                91,000              
          loss on disposition of equipment
        		                                              
          inducement charge for series c warrants
        		                                         -625 0 0 3,050,000  
          noncash expense of issuing shares to aspire capital
        		                                              
          prepaid expenses and other assets
        		                                 -197,356 100,000 16,000 -15,000 -28,928 -60,000 59,000 -49,000 57,630 86,000 -52,000 -7,000 -66,123 
          net cash from discontinued operations
        		                                              
          costs of essentialis acquisition
        		                                              
          purchase of property and equipment
        		                                 1,431 0 0 -4,000 320 0 -20,000 -19,000 -7,777 -32,000 -15,000 -1,000  
          cash paid for the cost issuance of common stock and common stock warrants
        		                                              
          proceeds from exercise of common stock options
        		                                     102 0   -427 0 282,000 12,000  
          net proceeds from issuance of series a convertible preferred
        		                                              
          net proceeds from issuance of series b convertible preferred
        		                                              
          redemption of series a convertible preferred stock in conjunction with issuance of series b convertible preferred stock
        		                                              
          series a convertible preferred transaction costs paid
        		                                              
          net increase in cash and equivalents
        		                                              
          supplemental disclosure of cash flow information
        		                                              
          cash paid for income taxes
        		                                              
          supplemental disclosures of noncash investing and financing information
        		                                              
          issuance of common stock for essentialis acquisition
        		                                              
          conversion of series a preferred to common stock
        		                                     -1,020,000 0 555,000 1,665,000      
          conversion of series b preferred to common stock
        		                                    6,000          
          series b preferred convertible stock transaction costs included in accounts payable
        		                                              
          fixed asset purchases included in accounts payable
        		                                              
          de-recognition of series b warrant liability through cashless exercise
        		                                              
          loss on disposition of property & equipment
        		                                              
          proceeds from sale of series a preferred convertible stock
        		                                      0 0 5,071,000      
          series a preferred convertible stock transaction costs paid
        		                                      0 0 -71,000      
          proceeds from sale of series b preferred stock
        		                                              
          redemption of series a preferred stock in conjunction with issuance of series b preferred stock
        		                                              
          continuing operations
        		                                  -1,471,000            
          discontinued operations
        		                                  -429,000            
          de-recognition of series b warrant liability
        		                                          -1,000 0 6,748,000  
          series b preferred transactions costs in accounts payable
        		                                              
          fixed asset purchases in accounts payable
        		                                              
          costs of essentialis acquistions included in accounts payable
        		                                    572,000          
          provision for deferred taxes
        		                                              
          acquisition of neoforce assets
        		                                              
          acquisition of bddi asset
        		                                              
          increase in restricted cash
        		                                         76,000 -76,000    
          proceeds from exercise of series a warrants
        		                                         0 0 0 156,000  
          proceeds from exercise of series b warrants
        		                                         -111,287 0 0 3,832,000  
          proceeds from issuance of common stock to aspire capital
        		                                              
          repayment of credit line
        		                                         471 0 0 -102,000  
          initial public offering costs paid
        		                                         -45,181 0 0 -530,000  
          series a preferred convertible stock transaction costs included in accounts payable
        		                                              
          de-recognition of series b warrant liability through cash exercise
        		                                              
          de-recognition of series a warrant liability through cash exercise
        		                                              
          bddi patent purchase consideration included in accrued liabilities
        		                                              
          shares issued as consideration for bddi patent purchase
        		                                              
          cashless exercise of 2010 and 2012 warrants
        		                                              
          contribution of series b warrants
        		                                              
          loss on disposition of property and equipment
        		                                      0       -273 
          cash paid for purchase of assets of neoforce group, inc.
        		                                              
          cash paid for patent acquisition
        		                                              
          proceeds from sale of series b preferred convertible stock
        		                                              
          redemption of series a preferred convertible stock in conjunction with issuance of series b convertible preferred
        		                                              
          proceeds from other exercise of series b warrants
        		                                          0 0 189,000  
          series b warrant transaction costs paid
        		                                          -131,000 0 -175,000  
          patent costs included in accrued liabilities
        		                                          -150,000    
          stock issuable in consideration for patent purchase
        		                                              
          de-recognition of series a warrant liability
        		                                          0 0 42,000  
          reduction in initial public offering costs payable
        		                                          0 0 45,000  
          cashless exercise of 2010/2012 warrants
        		                                          0 0 13,000  
          de-recognition of series b warrants contributed back to the company
        		                                          0 0 3,000  
          series b transaction costs in accounts payable
        		                                              
          series b warrant transaction costs included in accounts payable
        		                                              
          fixed asset costs included in accounts payable
        		                                        11,000      
          series b warrant transaction costs accrued and included in accrued compensation and other current liabilities
        		                                            131,000  
          non-cash interest expense relating to convertible promissory notes & amortization of discount on notes
        		                                              
          non-cash interest expense relating to line of credit
        		                                              
          other receivables
        		                                              
          accrued compensation & other current liabilities
        		                                              
          proceeds from issuance of series a convertible preferred
        		                                              
          proceeds from issuance of preferred stock warrants
        		                                              
          proceeds from issuance of convertible notes payable
        		                                             493,781 
          proceeds from line of credit
        		                                              
          proceeds from initial public offering
        		                                              
          initial public offering costs accrued and included in accounts payable
        		                                              
          beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes
        		                                              
          issuance of warrants for the purchase of convertible preferred stock in connection with notes payable
        		                                              
          2014 notes payable converted into units in the ipo
        		                                              
          2010/2012 notes payable converted into common stock in conjunction with ipo
        		                                              
          amortization of intangible assets
        		                                              
          change in fair value of preferred stock warrants
        		                                              
          non-cash interest expense relating to warrants and convertible promissory notes
        		                                              
          inventories
        		                                          -98,000 -72,000 -97,000  
          accrued liabilities
        		                                          103,000 502,000 115,000  
          issuance of 50,000 shares of common stock as consideration for patent acquisition
        		                                              
          proceeds from sale of property and equipment
        		                                              
          issuance of restricted common stock in exchange for intellectual property
        		                                              
          proceeds from issuance of warrants
        		                                              
          deferred offering costs paid
        		                                              
          issuance of warrants in connection with notes payable
        		                                              
          beneficial conversion feature in connection with convertible promissory notes
        		                                              
          deferred offering costs accrued and included in accounts payable